Jan Norum
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jan Norum has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
E A Wist
2 shared publicationsT Risberg
2 shared publicationsT. Risberg
Univ Hosp of North Norway, Tromsø, Norway; Univ of Tromsø, Tromsø, Norway
2 shared publicationsE. Solberg
Department of Oncology, University Hospital of Tromsø, P.O.B. 13, 9038 Tromsø, NorwayTel.: +47-77-626000 Fax: +47-77-626779
1 shared publicationJ. A. Olsen
Univ Hosp of North Norway, Tromsø, Norway; Univ of Tromsø, Tromsø, Norway
1 shared publicationS W Sørbye
Fagområdet Medisin Universitetet i Tromsø
1 shared publication
Latest Publications
- Open Access
- 22 November 2005
- Published by Elsevier in Annals of Oncology
- Vol. 17 (5) , 875-876
Reply to the Letter to the Editor, by J. Bonneterre and M. E. Bonneterre (Ann Oncol 2006; 17: 875)
I very much agree with the authors. However, in a model-based analysis we included the data present at the time when the study was done. The sensitivity analysis especially could have been enlarged by bringing in the moment of ‘never ending trastuzumab therapy’, but this was never an actual treatment in our country due to limited knowledge of the effects and the tremendous costs connected with such a strategy.
- 22 November 2005
- Published by Elsevier in Annals of Oncology
- Vol. 17 (5) , 875-876
Open AccessReply to the Letter to the Editor, by J. Bonneterre and M. E. Bonneterre (Ann Oncol 2006; 17: 875)
I very much agree with the authors. However, in a model-based analysis we included the data present at the time when the study was done. The sensitivity analysis especially could have been enlarged by bringing in the moment of ‘never ending trastuzumab therapy’, but this was never an actual treatment in our country due to limited knowledge of the effects and the tremendous costs connected with such a strategy.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 732
A monooclonal antibody against HER-2 (Trastuzumab) for metastatic breast cancer: A model-based cost-effectiveness analysis
732 Background: Trastuzumab has shown considerable activity in patients with metastatic breast cancer (MBC) that overexpress HER2. However, significant resources have been allocated to finance this new therapy. Due to ever increasing pressures on health care budgets, economic evaluations are requested in order to compare health effects with costs. We aimed to evaluate the cost effectiveness of trastuzumab in patients with metastatic breast cancer in a model based cost effectiveness analysis (CEA). Methods: All available data on trastuzumab in MBC presented at the San Antonio breast cancer conference in late 2003 and all data on the Medline in December 2003 were analysed for life years (LY) gained and quality of life (QoL) with regard to the use of this new monoclonal antibody. Randomised studies comparing standard chemotherapy with or without trastuzumab were focused. The costs were calculated according to Norwegian prices as in January 2003. Results: The LY gained ranged between 0.3–0.7 years. The median cost per patient treated was calculated €44,196 yielding costs per life year saved in the range between €63,137 - €162,417 depending on survival gain and discount rate employed. A sensitivity analysis documented the price of trastuzumab and the survival benefit the two major factors influencing the cost-effectiveness ratio. Conclusions: The economic evaluation indicates trastuzumab not cost effective in metastatic breast cancer. Reduced drug costs and/or improved survival may alter the Conclusion: No significant financial relationships to disclose.
- 1 June 2005
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (16) , 732
A monooclonal antibody against HER-2 (Trastuzumab) for metastatic breast cancer: A model-based cost-effectiveness analysis
732 Background: Trastuzumab has shown considerable activity in patients with metastatic breast cancer (MBC) that overexpress HER2. However, significant resources have been allocated to finance this new therapy. Due to ever increasing pressures on health care budgets, economic evaluations are requested in order to compare health effects with costs. We aimed to evaluate the cost effectiveness of trastuzumab in patients with metastatic breast cancer in a model based cost effectiveness analysis (CEA). Methods: All available data on trastuzumab in MBC presented at the San Antonio breast cancer conference in late 2003 and all data on the Medline in December 2003 were analysed for life years (LY) gained and quality of life (QoL) with regard to the use of this new monoclonal antibody. Randomised studies comparing standard chemotherapy with or without trastuzumab were focused. The costs were calculated according to Norwegian prices as in January 2003. Results: The LY gained ranged between 0.3–0.7 years. The median cost per patient treated was calculated €44,196 yielding costs per life year saved in the range between €63,137 - €162,417 depending on survival gain and discount rate employed. A sensitivity analysis documented the price of trastuzumab and the survival benefit the two major factors influencing the cost-effectiveness ratio. Conclusions: The economic evaluation indicates trastuzumab not cost effective in metastatic breast cancer. Reduced drug costs and/or improved survival may alter the Conclusion: No significant financial relationships to disclose.
- 1 January 2001
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 9 (1) , 55-60
Should cancer patients receive a copy of the medical record when visiting an out-patient clinic?
The aim of this study was to clarify the benefit and inconvenience to cancer patients of receiving a copy of the medical record following a visit to the out-patient clinic of the Department of Oncology, University Hospital of Tromsø, Norway. Between January and December 1998, after their attendance at the clinic a printout of the record made after the consultation was mailed to each of 199 patients seen by the same medical oncologist. A 15-item questionnaire was later mailed to 178 survivors in March 1999. The questionnaire had items on the use made of the copy report, side effects it might have occasioned, such as anxiety, worries and fear, and patients' general opinion of this procedure. There were 119 responders (67%), and 93 acknowledged receipt of the record. Most (96%) replied that the report had been beneficial; 78% had shown it to family members or friends; and 27% had shown it to other doctors. Only 9% had taken it with them when travelling. Such side effects as anxiety and worries were mentioned by only a few patients. Some 20% (mostly men) stated that medical terms had caused difficulties. Most patients in the study group (93%) recommended that the study practice should be introduced as standard procedure. Patients who considered receipt of the copy report of little value experienced the highest level of anxiety. In conclusion, cancer patients should be offered a copy of the medical record following an out-patient visit.
- 1 January 2001
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 9 (1) , 55-60
Should cancer patients receive a copy of the medical record when visiting an out-patient clinic?
The aim of this study was to clarify the benefit and inconvenience to cancer patients of receiving a copy of the medical record following a visit to the out-patient clinic of the Department of Oncology, University Hospital of Tromsø, Norway. Between January and December 1998, after their attendance at the clinic a printout of the record made after the consultation was mailed to each of 199 patients seen by the same medical oncologist. A 15-item questionnaire was later mailed to 178 survivors in March 1999. The questionnaire had items on the use made of the copy report, side effects it might have occasioned, such as anxiety, worries and fear, and patients' general opinion of this procedure. There were 119 responders (67%), and 93 acknowledged receipt of the record. Most (96%) replied that the report had been beneficial; 78% had shown it to family members or friends; and 27% had shown it to other doctors. Only 9% had taken it with them when travelling. Such side effects as anxiety and worries were mentioned by only a few patients. Some 20% (mostly men) stated that medical terms had caused difficulties. Most patients in the study group (93%) recommended that the study practice should be introduced as standard procedure. Patients who considered receipt of the copy report of little value experienced the highest level of anxiety. In conclusion, cancer patients should be offered a copy of the medical record following an out-patient visit.
- 6 August 2000
- Vol. 20, 2193-6
Screening for metastatic disease in newly diagnosed breast cancer patients. What is cost-effective?
Significant health care resources are today spent on diagnosing and treatment of early breast cancer. 98 consecutive patients referred to our oncological unit between January 1997 and June 1998 underwent an evaluation programme including thoracic X-ray, liver and bone scan and blood test. When findings suspected for metastatic disease were revealed, further examinations (CT-scan, MRI) were performed. Whereas the screening programme disclosed four cases (4%) of distant metastasis, several patients had to suffer the psychological distress of false positive results. One in three suspicious thoracic X-rays, two in two liver scans and 18 out of 21 suspected bone scans were concluded false positive in terms of metastatic disease. A screening programme including blood test and thoracic X-ray alone, would have mis-classified one out of 98 patients. This study indicated thoracic X-ray and blood test as being sufficient and 110 Pounds per patient screened could be saved.
- 6 August 2000
- Vol. 20, 2193-6
Screening for metastatic disease in newly diagnosed breast cancer patients. What is cost-effective?
Significant health care resources are today spent on diagnosing and treatment of early breast cancer. 98 consecutive patients referred to our oncological unit between January 1997 and June 1998 underwent an evaluation programme including thoracic X-ray, liver and bone scan and blood test. When findings suspected for metastatic disease were revealed, further examinations (CT-scan, MRI) were performed. Whereas the screening programme disclosed four cases (4%) of distant metastasis, several patients had to suffer the psychological distress of false positive results. One in three suspicious thoracic X-rays, two in two liver scans and 18 out of 21 suspected bone scans were concluded false positive in terms of metastatic disease. A screening programme including blood test and thoracic X-ray alone, would have mis-classified one out of 98 patients. This study indicated thoracic X-ray and blood test as being sufficient and 110 Pounds per patient screened could be saved.
- 11 February 2000
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 8 (2) , 110-114
Faith among patients with advanced cancer. A pilot study on patients offered "no more than" palliation
Spiritual wellbeing is an important topic in cancer care. Being religious is reported by patients facing dilemmas concerning the quality and meaning of life to be potentially helpful. However, the fear of death may be close to the surface and easily stimulated. The aim of this study was to clarify patients' attitudes to faith. Between February 1998 and February 1999, 20 patients aged 37–74 years and suffering from ten different incurable cancers were enrolled in the study. An interview technique focusing on the topic by way of an open question about faith was employed. The topic was only continued if the patient signalled a clear wish for this. Half the patients had a close relative present during the conversation, and an oncology nurse was present in all cases. Most patients (18, or 90%) intimated that the topic was of interest: 85% responded by saying they believed in God, and 75% reported that they prayed. A quarter (25%) mentioned that they had visited their local Lutheran pastor before their admission to hospital. One patient reported being a Jehovah's Witness and one, a member of the Norwegian Humanistically Ethical Association (HEA). Following the conversation, 4 patients requested a visit from the hospital chaplain, 1 asked for contact with the Salvation Army to be arranged, and 1 wanted to talk to the local leader of HEA. Following the conversation all patients were observed by a nurse, and no raised level of anxiety was reported. Sixteen of the patients died within a median of 18 (1–180) days after the conversation. In conclusion, most patients responded positively to a question about faith. The topic should be addressed in the treatment of patients with advanced disease. However, care must be taken to avoid frightening the patients. Patients' attitudes with regard to what death brings deserve respect.
- 11 February 2000
- Published by Springer Nature in Supportive Care in Cancer
- Vol. 8 (2) , 110-114
Faith among patients with advanced cancer. A pilot study on patients offered "no more than" palliation
Spiritual wellbeing is an important topic in cancer care. Being religious is reported by patients facing dilemmas concerning the quality and meaning of life to be potentially helpful. However, the fear of death may be close to the surface and easily stimulated. The aim of this study was to clarify patients' attitudes to faith. Between February 1998 and February 1999, 20 patients aged 37–74 years and suffering from ten different incurable cancers were enrolled in the study. An interview technique focusing on the topic by way of an open question about faith was employed. The topic was only continued if the patient signalled a clear wish for this. Half the patients had a close relative present during the conversation, and an oncology nurse was present in all cases. Most patients (18, or 90%) intimated that the topic was of interest: 85% responded by saying they believed in God, and 75% reported that they prayed. A quarter (25%) mentioned that they had visited their local Lutheran pastor before their admission to hospital. One patient reported being a Jehovah's Witness and one, a member of the Norwegian Humanistically Ethical Association (HEA). Following the conversation, 4 patients requested a visit from the hospital chaplain, 1 asked for contact with the Salvation Army to be arranged, and 1 wanted to talk to the local leader of HEA. Following the conversation all patients were observed by a nurse, and no raised level of anxiety was reported. Sixteen of the patients died within a median of 18 (1–180) days after the conversation. In conclusion, most patients responded positively to a question about faith. The topic should be addressed in the treatment of patients with advanced disease. However, care must be taken to avoid frightening the patients. Patients' attitudes with regard to what death brings deserve respect.
- 1 January 2000
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 39 (1) , 33-39
Adjuvant Cyclophosphamide, Methotrexate, Fluorouracil (CMF) in Breast Cancer: Is it Cost-effective?
Adjuvant chemotherapy (ACT) may expose patients to morbidity, with little gain in outcome. Treatment with CMF (cyclophosphamide, methotrexate, fluorouracil) has been the standard ACT in several countries for decades. In this model, efficacy, tolerability and quality of life data from the English-language literature were incorporated with Norwegian standard ACT practice and cost data in a cost-effectiveness/cost-utility approach. The CMF efficacy was calculated as 2.45 years saved per patient treated. The quality of life was assumed diminished by 0.33 (0-1 scale) for 6 months and the life years gained were valued Q=0.86. An 85% dose intensity was employed, one British pound (£1) was calculated as 12 NOK and a 5% discount rate was used. The total cost of adjuvant CMF, including amounts spent on drugs, administration, travelling and production loss, was calculated to £2365-£6253, depending on the method chosen. Money spent on drugs alone constituted 13-34%. The cost per life year saved was measured as £2170-£5737. A cost-utility approach revealed a cost per quality-adjusted life year (QALY) of £2973-£7860. Adjuvant CMF in breast cancer is cost-effective in Norway.
- 1 January 2000
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 39 (1) , 33-39
Adjuvant Cyclophosphamide, Methotrexate, Fluorouracil (CMF) in Breast Cancer: Is it Cost-effective?
Adjuvant chemotherapy (ACT) may expose patients to morbidity, with little gain in outcome. Treatment with CMF (cyclophosphamide, methotrexate, fluorouracil) has been the standard ACT in several countries for decades. In this model, efficacy, tolerability and quality of life data from the English-language literature were incorporated with Norwegian standard ACT practice and cost data in a cost-effectiveness/cost-utility approach. The CMF efficacy was calculated as 2.45 years saved per patient treated. The quality of life was assumed diminished by 0.33 (0-1 scale) for 6 months and the life years gained were valued Q=0.86. An 85% dose intensity was employed, one British pound (£1) was calculated as 12 NOK and a 5% discount rate was used. The total cost of adjuvant CMF, including amounts spent on drugs, administration, travelling and production loss, was calculated to £2365-£6253, depending on the method chosen. Money spent on drugs alone constituted 13-34%. The cost per life year saved was measured as £2170-£5737. A cost-utility approach revealed a cost per quality-adjusted life year (QALY) of £2973-£7860. Adjuvant CMF in breast cancer is cost-effective in Norway.
- 1 January 2000
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 12 (6) , 525-529
Oxaliplatin in Colorectal Cancer Patients Living in an Arctic or Subarctic Area: Significant Cold-Triggered Dysesthesias and Laryngeal Reactions
Oxaliplatin combined with 5-fluorouracil (5-FU) and folinic acid (FA) has been proven effective in colorectal cancer. However, side effects such as cold-triggered dysesthesia and laryngo-pharyngeal spasm have been reported. To clarify the side effects of oxaliplatin in a subarctic or arctic setting, a phase II study was performed. In October and November 1999, 8 patients with colorectal cancer were enrolled and treated with oxaliplatin (130 mg/m2 - day 1) and the FLv - Nordic regimen (5-FU 500 mg/m2 and leucovorin 100 mg for 2 days) every 3rd week as second- (6 pts) or third-line (2 pts) therapy. At evaluation in March 2000, 7 patients were alive and 6 PD, 1 SD and 1 PR were obtained. Acute laryngeal reaction was reported by 3 out of 8 patients and cold-triggered dysesthesia by all patients. Six available patients were interviewed by phone. Half of the interviewed patients recommend the therapy to be offered to other patients. In conclusion, oxaliplatin (130 mg/m2) therapy in arctic or subarctic areas during the winter introduces significant cold-triggered symptoms.
- 1 January 2000
- Published by Taylor & Francis in Journal of Chemotherapy
- Vol. 12 (6) , 525-529
Oxaliplatin in Colorectal Cancer Patients Living in an Arctic or Subarctic Area: Significant Cold-Triggered Dysesthesias and Laryngeal Reactions
Oxaliplatin combined with 5-fluorouracil (5-FU) and folinic acid (FA) has been proven effective in colorectal cancer. However, side effects such as cold-triggered dysesthesia and laryngo-pharyngeal spasm have been reported. To clarify the side effects of oxaliplatin in a subarctic or arctic setting, a phase II study was performed. In October and November 1999, 8 patients with colorectal cancer were enrolled and treated with oxaliplatin (130 mg/m2 - day 1) and the FLv - Nordic regimen (5-FU 500 mg/m2 and leucovorin 100 mg for 2 days) every 3rd week as second- (6 pts) or third-line (2 pts) therapy. At evaluation in March 2000, 7 patients were alive and 6 PD, 1 SD and 1 PR were obtained. Acute laryngeal reaction was reported by 3 out of 8 patients and cold-triggered dysesthesia by all patients. Six available patients were interviewed by phone. Half of the interviewed patients recommend the therapy to be offered to other patients. In conclusion, oxaliplatin (130 mg/m2) therapy in arctic or subarctic areas during the winter introduces significant cold-triggered symptoms.
- 1 January 2000
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 39 (2) , 189-193
Health, Life and Disability Insurance and Hereditary Risk for Breast or Colorectal Cancer
Fear of insurance discrimination affecting the insurance-seeker and family has been reported as the singlemost important reason why individuals choose not to undergo genetic testing. The eleven health insurers operating on the Norwegian market were mailed a questionnaire asking them to list their insurance products and evaluate two individuals' requests for insurance. The requests were constructed in order to illustrate a high genetic risk for (a) colorectal (HNPCC) and (b) breast cancer (BRCAI/BRCA2), respectively. Nine out of 11 insurers responded. While no restriction was documented concerning risk of BRCA1/BRCA2 and life insurance or disability pension, the premium paid by persons with susceptibility to HNPCC varied between the different insurers from standard to raised premiums. The product 'critical disease' insurance was refused or obtained at normal or raised premiums in both cases, depending on the insurer in question. On examining personal indemnity insurance, we found that the BRCA1/BRCA2-risk individual was offered insurance at the standard premium, whereas HNPCC-risk individuals were offered a standard or raised premium. Only the major Norwegian insurer is in fact diverging in its policies.
- 1 January 2000
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 39 (2) , 189-193
Health, Life and Disability Insurance and Hereditary Risk for Breast or Colorectal Cancer
Fear of insurance discrimination affecting the insurance-seeker and family has been reported as the singlemost important reason why individuals choose not to undergo genetic testing. The eleven health insurers operating on the Norwegian market were mailed a questionnaire asking them to list their insurance products and evaluate two individuals' requests for insurance. The requests were constructed in order to illustrate a high genetic risk for (a) colorectal (HNPCC) and (b) breast cancer (BRCAI/BRCA2), respectively. Nine out of 11 insurers responded. While no restriction was documented concerning risk of BRCA1/BRCA2 and life insurance or disability pension, the premium paid by persons with susceptibility to HNPCC varied between the different insurers from standard to raised premiums. The product 'critical disease' insurance was refused or obtained at normal or raised premiums in both cases, depending on the insurer in question. On examining personal indemnity insurance, we found that the BRCA1/BRCA2-risk individual was offered insurance at the standard premium, whereas HNPCC-risk individuals were offered a standard or raised premium. Only the major Norwegian insurer is in fact diverging in its policies.
- Open Access
- 1 February 1999
- Published by Elsevier in Annals of Oncology
- Vol. 10 (2) , 197-204
Breast cancer screening by mammography in Norway. Is it cost-effective?
- 1 February 1999
- Published by Elsevier in Annals of Oncology
- Vol. 10 (2) , 197-204
Open AccessBreast cancer screening by mammography in Norway. Is it cost-effective?
- 20 June 1998
- Vol. 118 (16) , 2468-70
[Cancer patients' perception of the examination period prior to treatment].
From July 1990 to July 1991 252 cancer patients admitted consecutively to the Department of Oncology, University Hospital of Tromsø, were included in a questionnaire-based study. The aim of the study was to examine the delays involved in the diagnosis and treatment of cancer. The study also focused on the psychological distress related to these periods of delay. A significant correlation between psychological distress and the actual length of delay (weeks) was revealed (p < 0.01). psychological distress was also correlated positively to the degree of depression (p < 0.01). Women found delays more distressing than men (p < 0.01). Patients from the northern areas (Troms and Finnmark counties) considered a cancer unit in Northern Norway to be of greater importance than those living in the southern area (Nordland county).
- 20 June 1998
- Vol. 118 (16) , 2468-70
[Cancer patients' perception of the examination period prior to treatment].
From July 1990 to July 1991 252 cancer patients admitted consecutively to the Department of Oncology, University Hospital of Tromsø, were included in a questionnaire-based study. The aim of the study was to examine the delays involved in the diagnosis and treatment of cancer. The study also focused on the psychological distress related to these periods of delay. A significant correlation between psychological distress and the actual length of delay (weeks) was revealed (p < 0.01). psychological distress was also correlated positively to the degree of depression (p < 0.01). Women found delays more distressing than men (p < 0.01). Patients from the northern areas (Troms and Finnmark counties) considered a cancer unit in Northern Norway to be of greater importance than those living in the southern area (Nordland county).